Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Ablynx N.V. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters span 7 distinct examiners and 6 distinct art units, indicating broad examiner distribution with some concentration of matters within the art-unit structure.
WANG, CHANG YU is the busiest examiner, with 1 pending matter. No examiner accounts for more than that stated workload, so prosecution management should be organized at the matter level.
The difference between examiner and art-unit counts means that examiner assignments are more numerous than art-unit assignments. Counsel can use art-unit groupings for technical and procedural coordination, while preserving examiner-specific analysis for amendments, interviews, and response arguments.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (43%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 1 (14%) |
| No statute on record | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WANG, CHANG YU | 1 | 33.4% | +53.7% |
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
| DAHLE, CHUN WU | 1 | 50.2% | +51.1% |
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| AEDER, SEAN E | 1 | 56.9% | +20.0% |
| SKELDING, ZACHARY S | 1 | 59.8% | +41.1% |
| IVICH, FERNANDO NMN | 1 | 52.4% | +72.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16310291 | IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | IVICH, FERNANDO NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17128570 | T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY | SKELDING, ZACHARY S | 12d |
| 18404145 | SERUM ALBUMIN BINDERS | WANG, CHANG YU | — |
| 18508693 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM | OUSPENSKI, ILIA I | — |
| 18493991 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | DAHLE, CHUN WU | — |
| 17697110 | GLYCOSYLATED IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | D' AMBROSIO, THEA | — |
| 17540310 | BISPECIFIC NANOBODIES | AEDER, SEAN E | — |
| 16310291 | IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | IVICH, FERNANDO NMN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| 1675 | 1 |
| 1641 | 1 |
| 1654 | 1 |
| 1642 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18404145 | SERUM ALBUMIN BINDERS | WANG, CHANG YU | 1675 | §112 | Non-Final OA | — | Pending | Jan 04, 2024 |
| 18508693 | AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM | OUSPENSKI, ILIA I | 1644 | §112 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18493991 | GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION | DAHLE, CHUN WU | 1641 | §103§112DP | Non-Final OA | — | Pending | Oct 25, 2023 |
| 17697110 | GLYCOSYLATED IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | D' AMBROSIO, THEA | 1654 | §112Other | Final Rejection | — | Pending | Mar 17, 2022 |
| 17540310 | BISPECIFIC NANOBODIES | AEDER, SEAN E | 1642 | — | Final Rejection | — | Pending | Dec 02, 2021 |
| 17128570 | T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY | SKELDING, ZACHARY S | 1644 | Other | Final Rejection | 12d | Pending | Dec 21, 2020 |
| 16310291 | IMPROVED PHARMACOKINETIC ASSAYS FOR IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS | IVICH, FERNANDO NMN | 1678 | §102§112 | Final Rejection | — | Pending | Dec 14, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAblynx N.V. has 7 pending office actions as of October 2026, spread across 6 art units and 7 examiners.
Chang Yu Wang has the most, with 1 of Ablynx N.V.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
